14 results about "Blood calcium" patented technology

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The present application relates to a kind of ammonium chloride calcium stick, belong to the technical field of feed.The ammonium chloride calcium stick includes the following components: calcium chloride, calcium sulfate, ammonium chloride, vitamin B6, modified cysteine, syringaldehyde, vitamin D3, sodium tripolyphosphate and solvent.Sodium tripolyphosphate maintains the stability of vitamin D3 and vitamin B6, wherein vitamin B6 inhibits prolactin synthesis, vitamin D3 promotes calcium absorption, prevents low blood calcium and excessive mammary secretion.The present application modifies cysteine by eugenol, increases its stability and dispersibility, and forms electrostatic interaction with sodium tripolyphosphate, forms a stable crosslinking network structure, increases the binding force between the coating layer and the raw material, prevents the loss of effective dry milk ingredients, and achieves better dry milk effect.

A liquid embolic composition of natural polymers, water, and angiographic contrast agents improves neurovascular interventions, making them more reliable, safe, and affordable. The embolic material is made of a single component activated by blood calcium ion, which triggers coagulation, and that offers superior mechanical stability and does not cause fragmentation in the target vessel. The material retains superior long-term mechanical durability after deployment and provides sufficient visualization under fluoroscopy with iodine-based angiographic contrast compounds or other radiopaque compositions. Described herein are aqueous solutions that enable a high concentration gellan gum (greater than 0.5 wt %) to retain sol state even at the range of body temperature (30-40° C.). This discovery means that it is possible to increase the concentration of gellan gum without losing its inject-ability, yet significantly improve its mechanical stability after delivery.

The present invention relates to the technical field of Chinese medicine compositions, and in particular to a Chinese medicine composition for treating secondary hyperparathyroidism and a preparation method thereof. Specifically, it is prepared from the following components by mass: 20-26 parts of Cordyceps sinensis, 20-26 parts of Eucommia ulmoides, 18-22 parts of Gecko, 18-22 parts of Cuscuta australis, 15-19 parts of Achyranthes bidentata, 14-18 parts of Peach Kernel, 13-17 parts of Panax notoginseng, 10-14 parts of Olibanum, 10-14 parts of Schisandra chinensis, 8-12 parts of Lotus Seed, 8-12 parts of Licorice, and 4-8 parts of Mulberry. The Chinese medicine composition provided by the present invention has excellent therapeutic effect on secondary hyperparathyroidism, and the patient's blood phosphorus, blood calcium, PTH, Scr, BUN and other indicators are significantly improved.

The invention provides an application of curcumin in preparation of a medicine for preventing and / or treating bone tissue radiation injury caused by Ra-223. Through in-vivo experiments, the protection effect of curcumin on bone tissue injury caused by Ra-223 radiation is evaluated. Experimental results show that curcumin can inhibit the change of blood calcium and serum phosphorus content caused by radium chloride, reduce apoptosis of bone tissue cells and inhibit excessive activation of osteoclasts. The invention not only provides an experimental basis for the application of curcumin in the aspect of radiation damage resistance, but also provides a new thought for developing novel anti-radiation drugs and treating skeleton diseases.

The invention discloses the application of the Chinese wolfberry fruit-glossy privet fruit and calcitriol composition in the medicine for treating postmenopausal osteoporosis for the first time, and through three-layer research of'in vitro cell-animal model-molecular pathway ', it is clear that the composition can bidirectionally regulate and control kidney vitamin D metabolic enzyme by activating'PI3K-AKT' signal pathway for the first time, so that the curative effect on postmenopausal osteoporosis is achieved. Further, the serum 25 hydroxyl vitamin D and blood calcium level are improved, and the bone mineral density is improved. The mechanism provides a modern molecular biology support for the traditional Chinese medicine theory of'kidney dominating bone ', and also establishes a new path of'regulating kidney metabolic enzyme to treat osteoporosis'. By optimizing the metabolic bone protection effect of the vitamin D, bone loss of ovariectomized mice is effectively delayed, meanwhile, the vitamin D and calcitriol play a synergistic effect, and the vitamin D has a multi-target bone protection effect in postmenopausal PMOP, has anti-osteoporosis activity and can be used for treating the PMOP.

This application relates to the field of intelligent medicine, and particularly relates to a method, system and device for predicting EPH after parathyroidectomy based on images. It includes obtaining parathyroid images of a patient; extracting EPH highly correlated features based on the parathyroid images to predict EPH after surgery to obtain a prediction result; wherein, the construction process of the EPH highly correlated features is as follows: S1: obtaining a parathyroid image set, EPH grouping labels, and blood calcium concentration labels of the patient; S2: extracting primary features from the parathyroid image set based on the EPH grouping labels and blood calcium concentration labels; S3: performing feature screening on the primary features to obtain the EPH highly correlated features. This method predicts whether EPH occurs after parathyroidectomy for patients with secondary hyperparathyroidism through radiomics features, and has good clinical value.

The invention discloses a 96-well plate trace detection method for milk cow blood calcium, and belongs to the field of blood calcium detection. The invention aims to overcome the defects of high reagent and sample consumption, complicated experimental operation, time consumption, incapability of large-scale detection and the like in a traditional method for measuring the blood calcium of the dairy cow by using a laboratory biochemical analyzer. The method comprises the following steps: carrying out empty caudal vein blood collection, centrifugation, serum quick-freezing and storage on postpartum lactating cows for 1-14 days in the morning; recovering the refrigerated serum sample and the blood calcium biochemical kit to room temperature, and preparing a Ca determination reagent; determining the reaction temperature by using the regression equation and the correlation coefficient value; determining a volume ratio; finally, determining the reaction time; and determining reaction conditions to measure the concentration of calcium ions in the cow blood. The method provided by the invention can effectively improve the capability of pasture detection and diagnosis of hypocalcemia of dairy cows.

The invention provides an rTGA technology fish oil composite capsule and application thereof to cardiovascular and bone health. According to the capsule, a high-purity fish oil substrate with the total content of EPA and DHA being larger than or equal to 75% is prepared through an rTGA technology, the high-purity fish oil substrate is compounded with vitamin D3 and a composite antioxidant in a specific proportion, and then packaging is conducted through a double-layer microencapsulation embedding technology (an inner layer complex coacervation wall material and an outer layer enteric coating). The invention solves the problems of poor compounding stability of high-purity Omega-3 and vitamin D3 and lack of synergistic effect verification. The obtained product can significantly improve the blood fat level (reduce TG and TC) and bone health indexes (increase blood calcium and improve bone mineral density) at the same time, and an innovative scheme is provided for developing dietary supplements with clear cardiovascular and bone dual health functions.

The invention relates to a clinical diagnosis model for early diagnosis of fever with thrombocytopenia syndrome (SFTS) complicated by acute pancreatitis (AP) and a construction method thereof. The model is constructed through Logistic regression analysis and LASSO regression analysis on the basis of indexes such as virus load (DBV RNA), thrombin time (TT), amylase (AMY) and blood calcium (Ca). The model shows good distinction degree and calibration degree in a training queue and a verification queue, can effectively predict the risk of concurrent AP of the SFTS patient, and has relatively high clinical practicability and prediction accuracy.

The present invention provides a saliva-associated lactobacillus and its application for promoting calcium absorption and bone growth. The preservation number of saliva-associated lactobacillus LS60 is CGMCC No.30305. The present invention also provides the culture supernatant or dead bacteria of the saliva-associated lactobacillus. The saliva-associated lactobacillus LS60 strain is beneficial for intestinal cells to absorb calcium ions, promotes osteoblast differentiation, and increases the blood calcium and bone calcium content of mice. Most importantly, the probiotic can increase the level of IGF-1 and promote the growth of the femur of mice; in addition, the LS60 strain can also produce high GABA; in summary, the saliva-associated lactobacillus LS60 of the present invention has the potential to promote calcium absorption and bone growth.

The present invention provides a fast and long-acting calcium supplement preparation for dairy cows after childbirth and a preparation method thereof. The fast and long-acting calcium supplement preparation for dairy cows after childbirth comprises a core material and a coating material coated on the periphery of the core material, wherein the core material is composed of two parts, segment A and segment B; segment A of the core material is composed of anhydrous calcium chloride and a carrier A that can be quickly dissolved and released in the rumen; segment B of the core material is composed of anhydrous calcium chloride and a carrier B that can be slowly released in the rumen; the coating material comprises coating material A and coating material B; coating material A is coated on the periphery of segment A of the core material, and coating material B is coated on the periphery of segment B of the core material. The present invention adopts a combination of fast-release segment A and slow-release segment B to obtain a composite coated calcium rod material, which can maintain a high blood calcium level for a long time (more than 24 hours) while rapidly improving the blood calcium of postpartum dairy cows; at the same time, the formula contains active 1,25-dihydroxyvitamin D3 that has passed the rumen, which stimulates the intestine to absorb more calcium and improves the absorption and utilization rate of calcium.

The invention discloses a microfluidic device based on an MMPs-DNAzyme-PMPs compound and a detection method, and belongs to the technical field of biological detection. According to the invention, DNAzyme molecules are combined with magnetic particles (MMPs) and polystyrene particles (PMPs), and the obtained composite structure (MMPs-DNAzyme-PMPs) can trigger a DNAzyme cutting reaction in the presence of calcium ions, so that free PMPs are released. In combination with an automatic capillary tube driving micro-fluidic device, the PMPs are captured and accumulated by utilizing the characteristic that the aperture of the tail end of a particle dam is smaller than the diameter of the free PMPs, a visual length strip is formed, and rapid quantitative detection of the blood calcium ion concentration can be realized through naked eyes or a mobile phone camera. The enrichment and concentration visualization of the calcium ions can be realized only by using a trace amount of blood sample, and the method is suitable for instant detection of families and medical sites.

The invention provides a medicine for treating diseases related to bacterial infection and application of the medicine, and particularly relates to the field of medicine. According to the invention, MRSA bacterial calcification can be induced in a targeted manner under the blood calcium ion level with physiological concentration, MRSA death is caused by inhibiting bacterial aerobic respiration and energy metabolism, and bacterial virulence and quorum sensing are inhibited. After in-vivo systemic injection of a mouse, the MRSA site can be efficiently targeted, MRSA calcification sterilization is induced, calcified bacteria can enhance inherent sterilization immunity of a host with a mononuclear macrophage system as a main part, macrophages are promoted to be polarized into an inflammatory macrophage state, the bacterial phagocytic ability and the inflammatory factor secretion ability of the host are enhanced, and the anti-inflammatory effect of the host is improved. Therefore, mouse chronic pulmonary infection and chronic osteomyelitis caused by MRSA are effectively treated, the survival rate of mouse pneumonia and osteomyelitis is remarkably improved, and the bone density of patients with osteomyelitis is improved. The invention has the potential to be developed into a novel non-antibiotic bactericidal drug for treating intractable pathogen infection such as drug-resistant bacteria and the like.